PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aligos Therapeutics, Inc. (ALGS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS01626L1052
CUSIP01626L105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$39.34M
EPS (TTM)-$1.05
PE Ratio8.03
PEG Ratio-14.47
Total Revenue (TTM)$6.91M
Gross Profit (TTM)$4.78M
EBITDA (TTM)-$65.66M
Year Range$0.35 - $1.20
Target Price$7.00
Short %4.83%
Short Ratio5.27

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Aligos Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aligos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%FebruaryMarchAprilMayJuneJuly
-96.30%
59.47%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aligos Therapeutics, Inc. had a return of -17.17% year-to-date (YTD) and -40.22% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-17.17%16.48%
1 month21.95%1.67%
6 months-19.24%14.21%
1 year-40.22%21.98%
5 years (annualized)N/A13.13%
10 years (annualized)N/A10.91%

Monthly Returns

The table below presents the monthly returns of ALGS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20243.92%43.48%-1.01%-21.94%-22.88%-40.68%-17.17%
2023103.57%-24.74%-40.14%32.72%-2.59%-14.07%-8.34%-3.26%-13.24%-19.68%16.67%-5.14%-30.33%
2022-73.13%-24.14%-11.16%-45.12%9.32%-6.20%2.48%0.81%-12.00%-4.55%-4.76%-4.70%-91.97%
20211.88%2.02%-20.88%13.10%8.40%-26.88%-28.53%17.02%-9.03%2.71%-3.83%-22.52%-57.07%
20200.61%25.23%47.78%86.20%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALGS is 22, indicating that it is in the bottom 22% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ALGS is 2222
ALGS (Aligos Therapeutics, Inc.)
The Sharpe Ratio Rank of ALGS is 2323Sharpe Ratio Rank
The Sortino Ratio Rank of ALGS is 2626Sortino Ratio Rank
The Omega Ratio Rank of ALGS is 2727Omega Ratio Rank
The Calmar Ratio Rank of ALGS is 2323Calmar Ratio Rank
The Martin Ratio Rank of ALGS is 1111Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aligos Therapeutics, Inc. (ALGS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALGS
Sharpe ratio
The chart of Sharpe ratio for ALGS, currently valued at -0.52, compared to the broader market-2.00-1.000.001.002.003.00-0.52
Sortino ratio
The chart of Sortino ratio for ALGS, currently valued at -0.42, compared to the broader market-4.00-2.000.002.004.00-0.42
Omega ratio
The chart of Omega ratio for ALGS, currently valued at 0.95, compared to the broader market0.501.001.502.000.95
Calmar ratio
The chart of Calmar ratio for ALGS, currently valued at -0.43, compared to the broader market0.001.002.003.004.005.006.00-0.43
Martin ratio
The chart of Martin ratio for ALGS, currently valued at -1.31, compared to the broader market-30.00-20.00-10.000.0010.0020.00-1.31
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.99, compared to the broader market-2.00-1.000.001.002.003.001.99
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.81, compared to the broader market-4.00-2.000.002.004.002.81
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.35, compared to the broader market0.501.001.502.001.35
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.59, compared to the broader market0.001.002.003.004.005.006.001.59
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.44, compared to the broader market-30.00-20.00-10.000.0010.0020.007.44

Sharpe Ratio

The current Aligos Therapeutics, Inc. Sharpe ratio is -0.52. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Aligos Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00FebruaryMarchAprilMayJuneJuly
-0.52
1.99
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aligos Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%FebruaryMarchAprilMayJuneJuly
-98.43%
-1.97%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aligos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aligos Therapeutics, Inc. was 99.00%, occurring on Jun 28, 2024. The portfolio has not yet recovered.

The current Aligos Therapeutics, Inc. drawdown is 98.43%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99%Jan 21, 2021865Jun 28, 2024
-22.62%Nov 17, 202010Dec 1, 20208Dec 11, 202018
-20.62%Dec 24, 20204Dec 30, 20209Jan 13, 202113
-11.11%Oct 19, 20202Oct 20, 20201Oct 21, 20203
-10.79%Nov 10, 20201Nov 10, 20203Nov 13, 20204

Volatility

Volatility Chart

The current Aligos Therapeutics, Inc. volatility is 26.80%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%FebruaryMarchAprilMayJuneJuly
26.80%
2.94%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aligos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

P/E Ratio

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Aligos Therapeutics, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items